ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.404 5年インパクトファクター: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 40, 2020 巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i5.40
pages 449-461

A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases

Moutih Rafei
Institute for Research in Immunology and Cancer, University of Montreal, Montreal, Quebec Canada
Jacques Galipeau
Winship Cancer Institute, Departments of Hematology and Medical Oncology, Pediatrics & Medicine, Emory University, Atlanta, GA, USA

要約

Autoimmune diseases represent one of the most challenging clinical entities with unmet medical needs, so the continued development of novel therapeutics is well justified. Most autoimmune diseases are marked by the infiltration of lymphomyeloid cells in target tissues, leading to inflammation and tissue damage. This process is guided by chemokines that act as signaling bridges amidst a complex network of immune cells. For example, monocytes are believed to be the primary cell type responsible for pathology initiation and tissue damage, while T lymphocytes are thought to orchestrate the process by secreting more cytokines/chemokines to amplify leukocyte homing. Many studies have addressed the molecular basis of monocyte recruitment in different autoimmune diseases, and the conclusions pointed to a major role played by monocyte chemoattractant protein 1 (MCP-1), also known as CC chemokine ligand 2 (CCL2), and its cell-surface receptor, CC chemokine receptor (CCR) 2. These findings suggest that by interfering with CCL2 or its receptor, it is possible to inhibit the progression of CCR2-dependent diseases. Therefore, future therapy design targeting a maladapted immune response could target chemokine receptors starting with the CCL2-CCR2 axis.


Articles with similar content:

Pathogenesis of HIV-1 Associated Neurodegeneration
Critical Reviews™ in Neurobiology, Vol.10, 1996, issue 1
Lennart Mucke, Eliezer Masliah, Nianfeng Ge
Transcription Factors and Th17 Cell Development in Experimental Autoimmune Encephalomyelitis
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Guobing Chen, M. Frances Shannon
Structure of IL-10 and Its Role in Autoimmune Exocrinopathy
Critical Reviews™ in Immunology, Vol.20, 2000, issue 2
Ichiro Saito
Regulation of Dendritic- and T-Cell Fate by Injury-Associated Endogenous Signals
Critical Reviews™ in Immunology, Vol.29, 2009, issue 1
Marco E. Bianchi, Annalisa Capobianco, Angelo A. Manfredi, Patrizia Rovere-Querini
Regulation of Regulatory T Cells: Role of Dendritic Cells and Toll-Like Receptors
Critical Reviews™ in Immunology, Vol.26, 2006, issue 4
Dieter Kabelitz, Daniela Wesch, Hans-Heinrich Oberg